About us

Our name, Enara Bio®, is derived from an Arabic word meaning illumination, enlightenment and bringing light into the darkness.

We are the leaders in discovering and validating Dark Antigens®, a rich source of novel cancer targets derived from areas of the genome previously considered to be ‘dark’ or non-coding. Through our proprietary EnTiCE® platform, we are developing first-in-class bispecific T-cell engagers against novel targets to improve treatment outcomes for broad populations of cancer patients.

Enara Bio is backed by prominent life science investors, including RA Capital, Pfizer Ventures, M Ventures, Samsara BioCapital and SV Health Investors. We collaborate with world-leading companies and academic institutions, such as Boehringer Ingelheim and the Francis Crick Institute, to help drive our differentiated science-led approach.

Enara Bio Our Story Poster

Leadership Team

Kevin Pojasek
President and CEO
Stacey Davis
CBO and CFO
Scott Drutman
CMO
Joseph Dukes
CSO

Board of Directors

Scientific Advisors & Founders

Investors

Scott Drutman

CMO

Scott is an oncologist physician scientist who is passionate about translating scientific discoveries into treatments for cancer patients. Prior to joining Enara, Scott was Chief Medical Officer and Head of Research & Development at Volastra Therapeutics. Previously, he worked in oncology clinical development at Regeneron Pharmaceuticals in both early and late development across multiple assets and tumor types. Prior to Regeneron, Scott was an Instructor at The Rockefeller University, where his research program focused on immunology and human genetics.

Scott completed his postdoctoral fellowship at The Rockefeller University, his medical oncology clinical fellowship and additional training in early phase immuno-oncology at Memorial Sloan Kettering Cancer Center, and his internal medicine residency at New York-Presbyterian/Weill Cornell. He received an undergraduate degree from Reed College, an M.D./Ph.D. from NYU School of Medicine, and an M.S. in clinical and translational investigation from The Rockefeller University.